• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • Opinion
    • Going for Goals

    Opinion: How to generate increased investment to tackle antimicrobial resistance

    Increasing antimicrobial resistance is a continued threat to global health as well as economies. Merck Sharp & Dohme’s Paul Schaper believes increased investment is key, explaining the role both governments and the private sector need to play to ensure a healthy and prosperous future.

    By Paul Schaper // 19 July 2017
    A shot of a petri dish. Photo by: Merck Sharp & Dohme

    At the recent Hamburg summit, G-20 leaders reaffirmed their commitment to addressing antimicrobial resistance as a growing threat to public health and economic growth. Leading organizations including the United Nations, the G-7 and World Health Organization have called for joint action against AMR in recent years. Some have gone so far as to predict AMR will cause tens of millions of deaths and trillions of dollars in economic costs, if left unaddressed. A consistent theme of these analyses is that bacteria are evolving and developing resistance faster than we have been able to discover and develop novel antimicrobials to combat them. In fact, pharmaceutical pipelines consistently show a decrease in antibiotic research and development programs when the need for new medicines is increasing.

    To ramp up antimicrobial R&D, innovative financing solutions that will incentivize sustained investment in this field are needed. The current model fails to provide a sufficient economic return to spur the level of R&D investment that society needs. Even when new, effective antibiotics are approved, the return on investment for the developer is generally low compared to other therapeutic areas due to the typically slow uptake of these medicines. New pharmaceuticals that can target resistant bacteria are used only for the most seriously ill patients with the most resistant infections, in order to guard against the development of resistance. In addition, the value that health, economic and reimbursement systems generally assign to new antibiotics undervalues the benefits that they bring. It limits the price that hospitals and insurers are willing to pay for novel antibiotics, reducing the financial incentive of investing in their development.

    The role of governments in increasing investment

    Governments have taken some steps to start to address the negative economics of antibiotic R&D. Some have established grants that provide support for the early stage development of antibiotics. Legislation has been introduced in the United States to address issues of hospital reimbursement, and the recently issued European Union One Health Action Plan against AMR calls for new efforts to address the valuation of novel antibiotics in health economic analyses.  

    “To ramp up antimicrobial R&D, innovative financing solutions that will incentivize sustained investment in this field are needed. The current model fails to provide a sufficient economic return to spur the level of R&D investment that society needs.”

    — Paul Schaper, Executive Director, Global Public Policy, Merck Sharp & Dohme

    A key gap is progress on proposals for a sufficiently large, predictable and sustainable outcomes-based mechanism that provides an adequate return on investment to incentivize the private sector to take on the necessary risk and uncertainty that comes with investing in the development of new antibiotics. The antibiotic marketplace presents unique challenges — at the same time that we want to incentivize development of new antibiotics, we must also be careful stewards of their use to slow the pace of emerging antibiotic resistance. A novel R&D incentive mechanism needs to reduce the percentage of the return on investment achieved through sales volume, but it should also harness the ability of existing market-based models that have effectively driven investment and innovation in other therapeutic areas. Given the unique challenges of the antibiotic market, governments have a role to facilitate conditions to enable a sustainable environment for investment in antimicrobial R&D.

    The need for incentives

    In order to restock our medicine chest with effective antibiotics, novel incentive structures are needed. These can and should incorporate market-based mechanisms to more effectively and efficiently allocate limited resources, attract sustainable private sector investment and reward successful innovation. Grant-based push mechanisms and public-private development partnerships have had mixed success in delivering tangible results for the public resources invested. Novel incentive mechanisms, such as market entry incentive payments for the development of products that address pathogens prioritized by WHO or the U.S. Centers for Disease Control and Prevention, can play an important role in enhancing the economic feasibility of antibiotic R&D. By incorporating market-based mechanisms, these novel incentives can retain the benefits of market-based private sector investment and competition.

    See more stories on Going for Goals:

    ► Opinion: More money alone won't meet SDG 3

    ► Opinion: How technology is helping India move toward smart service delivery

    ► Innovative financing for health: Insights from the Grand Challenges Award Repository

    ► Opinion: High returns await those investing in population health

    ► How venture capital can help finance the SDGs

    I’m encouraged by the strides made recently to bring the critical issues of antimicrobial resistance to the forefront and the robust engagement of the private sector. In January 2016, MSD joined more than 100 biopharmaceutical, generic and diagnostic companies in signing a declaration at the World Economic Forum that sets out bold commitments and calls on governments and industry to take joint action against AMR.

    The global community must seize this moment and act to ensure a future where, even in the face of the ongoing microbial evolution, we continue to enjoy the health and economic benefits of having effective antimicrobial treatments. With the support of key stakeholders across the globe to stimulate antimicrobial R&D and advocate for innovative financing models, I am confident that we will.

    To learn more about the industry’s commitment to addressing AMR, visit the Industry Roadmap for Progress on Combating Antimicrobial Resistance and the International Federation of Pharmaceutical Manufacturers & Associations’ policy position on AMR.

    Over 10 weeks Devex and our partners will take an in-depth look at the innovative financing mechanisms driving forward the 2030 sustainable development agenda. We’ll explore how the funding gap can be filled, ask how cross-sector collaboration can lead to improved global health care, and look at what it takes to build successful partnerships for change. Join us as we examine the innovative financing powering the Global Goals by tagging #Going4Goals and @devex.

    • Funding
    • Worldwide
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
    The views in this opinion piece do not necessarily reflect Devex's editorial views.

    About the author

    • Paul Schaper

      Paul Schaper

      Paul Schaper leads global policy efforts at ‎Merck Sharp & Dohme on infectious diseases, including antibiotics/antifungals, HIV and hepatitis. Since 2013, he has served as the private sector representative on the board of the Global Fund for HIV, TB and Malaria. Schaper earned his B.A. and master’s degrees in public health policy and business administration from Emory University and another master’s degree in clinical psychology from Georgia State University.

    Search for articles

    Related Stories

    Global HealthHow unregulated antibiotics are fueling drug-resistant UTIs

    How unregulated antibiotics are fueling drug-resistant UTIs

    Global HealthOpinion: A new panel could be our best weapon against drug resistance

    Opinion: A new panel could be our best weapon against drug resistance

    Global healthOpinion: Global health is at risk. Sustainable infrastructure will help

    Opinion: Global health is at risk. Sustainable infrastructure will help

    Development FinanceOpinion: In Sevilla, a moment to bridge the development finance chasm

    Opinion: In Sevilla, a moment to bridge the development finance chasm

    Most Read

    • 1
      The power of diagnostics to improve mental health
    • 2
      Lasting nutrition and food security needs new funding — and new systems
    • 3
      The UN's changing of the guard
    • 4
      Opinion: Urgent action is needed to close the mobile gender gap
    • 5
      The top local employers in Europe
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement